Cassava Sciences' Simufilam Improves Cognition and Behavior in Alzheimer's Disease in Interim ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim ... Cassava Sciences, Inc.February 2, 2021 GMT - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 - - Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program - AUSTIN, Texas, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis fr...
Source: apnews.com